BioAge Labs (NASDAQ:BIOA) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of BioAge Labs (NASDAQ:BIOA) from a hold rating to a sell rating in a research report sent to investors on Monday.

A number of other research analysts have also commented on BIOA. Citigroup upped their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Down 0.5%

BioAge Labs stock opened at $19.51 on Monday. The company’s 50-day moving average price is $14.08 and its two-hundred day moving average price is $8.51. The stock has a market cap of $699.43 million, a P/E ratio of -12.84 and a beta of 1.38. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Activity

In other news, insider Paul D. Rubin sold 18,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $12.00, for a total transaction of $216,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the transaction, the chief financial officer owned 22,408 shares in the company, valued at $441,437.60. The trade was a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 347,004 shares of company stock worth $5,673,859. 20.82% of the stock is currently owned by company insiders.

Institutional Trading of BioAge Labs

A number of institutional investors and hedge funds have recently made changes to their positions in BIOA. Vanguard Group Inc. increased its stake in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after acquiring an additional 93,694 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares in the last quarter. Millennium Management LLC increased its stake in shares of BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after purchasing an additional 270,479 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after buying an additional 173,388 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its position in shares of BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after buying an additional 101,085 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.